Actively Recruiting
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Led by Sun Yat-sen University · Updated on 2023-10-24
150
Participants Needed
1
Research Sites
385 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate genomic architecture, cancer evolution and their relationship with clinical outcomes in EGFR-mutant NSCLC.
CONDITIONS
Official Title
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Histologically or cytologically confirmed non-small-cell lung cancer
- ECOG Performance Status of 0 to 2
- EGFR mutations confirmed by tissue or peripheral blood
- Ability to provide tumor tissue samples (fresh or archived)
- Willingness to participate voluntarily and sign informed consent
You will not qualify if you...
- History of other cancers within the past 5 years, except treated basal cell carcinoma of the skin or carcinoma in situ
- Inability to provide sufficient tumor tissue for analysis
- Active, unstable systemic diseases such as active infection, uncontrolled hypertension, heart failure (NYHA class 62; II), unstable angina, acute coronary syndrome, severe arrhythmia, severe liver, kidney, or metabolic diseases, or HIV infection
- Inability to comply with or complete the study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guanzhou, China, 510060
Actively Recruiting
Research Team
S
Shen Zhao, MD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here